Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 57,787
  • Shares Outstanding, K 50,690
  • Annual Sales, $ 18,720 K
  • Annual Income, $ -30,100 K
  • 36-Month Beta 2.65
  • Price/Sales 3.14
  • Price/Cash Flow 0.00
  • Price/Book 0.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.93 +22.58%
on 08/29/17
1.38 -17.39%
on 09/06/17
+0.16 (+16.33%)
since 08/22/17
3-Month
0.93 +22.58%
on 08/29/17
2.02 -43.56%
on 06/23/17
-0.87 (-43.28%)
since 06/22/17
52-Week
0.84 +35.71%
on 11/04/16
3.84 -70.31%
on 03/02/17
-0.33 (-22.45%)
since 09/22/16

Most Recent Stories

More News
Hot Stock: Infinity Pharmac, Shares Gain 13.2% (INFI)

Infinity Pharmac (NASDAQ:INFI) is one of today's best performing low-priced stocks, up 13.2% to $1.07 on 1.6x average daily volume. Thus far today, Infinity Pharmac has traded 784,000 shares, vs. average...

INFI : 1.14 (-1.72%)
Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma

If you want a Stock Review on IMGN, INCY, INFI, or JAZZ then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com is currently focused...

JAZZ : 147.89 (+0.07%)
IMGN : 6.55 (+0.77%)
INCY : 110.85 (-3.65%)
INFI : 1.14 (-1.72%)
Infinity (INFI) Q2 Loss Wider than Expected, View Intact

Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.

INFI : 1.14 (-1.72%)
ABBV : 87.48 (+0.08%)
GILD : 83.27 (+0.79%)
BMY : 63.36 (+0.05%)
Infinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, August 3, 2017, at 4:30 p.m. ET to review its second quarter 2017 financial results and provide an update on the company....

INFI : 1.14 (-1.72%)
Infinity to Participate in Three Upcoming Conferences

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase...

INFI : 1.14 (-1.72%)
Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound?

Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 1.14 (-1.72%)
Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1

Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago...

GALE : 0.35 (unch)
BTX : 2.80 (+0.36%)
INFI : 1.14 (-1.72%)
CPRX : 2.44 (unch)
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

GALE : 0.35 (unch)
BTX : 2.80 (+0.36%)
ECYT : 1.39 (+0.72%)
INFI : 1.14 (-1.72%)
Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised

Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.

GALE : 0.35 (unch)
BTX : 2.80 (+0.36%)
INFI : 1.14 (-1.72%)
VRX : 14.01 (-1.55%)
Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View

Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.

GALE : 0.35 (unch)
BTX : 2.80 (+0.36%)
PRTA : 64.76 (-0.45%)
INFI : 1.14 (-1.72%)
RHHBY : 32.0200 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Support & Resistance

2nd Resistance Point 1.22
1st Resistance Point 1.18
Last Price 1.14
1st Support Level 1.10
2nd Support Level 1.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.